Abstract：Objective：To observe the clinical effect of Xiao'er Rekeqing capsules combined with montelukast sodium for cough variant asthma(CVA) of children. Methods： A total of 160 cases of CVA children were selected and divided into the observation group and the control group according to different treatment methods，80 cases in each group. The control group was treated with montelukast sodium， and the observation group was additionally treated with Xiao'er Rekeqing capsules based on the treatment of the control group. Both groups were treated for two weeks. Before and after treatment， the frequency and degree of cough， the lung function index， and the level of urinary leukotriene E4(LTE4) were compared between the two groups. Results：After treatment，scores of the frequency and degree of cough in the two groups were decreased when compared with those before treatment(P＜0.05)，and the scores in the observation group were lower than those in the control group(P＜0.05). After treatment， maximal expiratory flow at 75% of vital capacity(MEF75) in the observation group was increased when compared with that before treatment(P＜0.05)， and higher than that in the control group at the same period(P＜0.05). When compared maximal expiratory flow at 25% (MEF25) and 50% (MEF50) of vital capacity between the two groups，there was no significance in differences(P＞0.05). After treatment，levels of urinary LTE4 in the two groups were decreased when compared with those before treatment(P＜0.05)，and the level in the observation group was lower than that in the control group(P＜0.05). Conclusion： In the treatment of CVA of children， the therapy of Xiao'er Rekeqing capsules combined with montelukast sodium can significantly decrease the degree of cough，improve the lung function，and reduce urinary LTE4 level.